Abstract
Malaria, caused by protozoa of the genus Plasmodium, remains one of the most dreadful infectious diseases worldwide killing more than 1 million people per year. The emergence of multidrug-resistant parasites highly demands a steadfast and continuous search not only for new targets but also for new anti-infectives addressing the known ones. As proteases in general have been proven to be excellent drug targets and the development of inhibitors has frequently resulted in approved drugs, this review will only focus on the proteases of Plasmodium falciparum as drug targets. The completion of the sequencing of the Plasmodium falciparum genome in 2002 lead to the discovery of nearly 100 putative proteases encoded therein. Within this review, only those proteases and inhibitors thereof will be discussed in more detail, in which their biological function has been determined undoubtedly or in those cases, in which the development of specific inhibitors has significantly contributed to the understanding of the underlying biological role of the respective protease thus validating the role as promising drug target.
Keywords: Malaria, Plasmepsin, Falcipain, protease inhibitors
Current Topics in Medicinal Chemistry
Title: Proteases of Plasmodium falciparum as Potential Drug Targets and Inhibitors Thereof
Volume: 10 Issue: 3
Author(s): Christof Wegscheid-Gerlach, Hans-Dieter Gerber and Wibke E. Diederich
Affiliation:
Keywords: Malaria, Plasmepsin, Falcipain, protease inhibitors
Abstract: Malaria, caused by protozoa of the genus Plasmodium, remains one of the most dreadful infectious diseases worldwide killing more than 1 million people per year. The emergence of multidrug-resistant parasites highly demands a steadfast and continuous search not only for new targets but also for new anti-infectives addressing the known ones. As proteases in general have been proven to be excellent drug targets and the development of inhibitors has frequently resulted in approved drugs, this review will only focus on the proteases of Plasmodium falciparum as drug targets. The completion of the sequencing of the Plasmodium falciparum genome in 2002 lead to the discovery of nearly 100 putative proteases encoded therein. Within this review, only those proteases and inhibitors thereof will be discussed in more detail, in which their biological function has been determined undoubtedly or in those cases, in which the development of specific inhibitors has significantly contributed to the understanding of the underlying biological role of the respective protease thus validating the role as promising drug target.
Export Options
About this article
Cite this article as:
Wegscheid-Gerlach Christof, Gerber Hans-Dieter and Diederich E. Wibke, Proteases of Plasmodium falciparum as Potential Drug Targets and Inhibitors Thereof, Current Topics in Medicinal Chemistry 2010; 10 (3) . https://dx.doi.org/10.2174/156802610790725461
DOI https://dx.doi.org/10.2174/156802610790725461 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy
Anti-Cancer Agents in Medicinal Chemistry Antiproliferative and Proapoptotic Effects of Proteasome Inhibitors and their Combination with Histone Deacetylase Inhibitors on Leukemia Cells
Cardiovascular & Hematological Disorders-Drug Targets Role of Natural Phenolic Compounds in Cancer Chemoprevention via Regulation of the Cell Cycle
Current Pharmaceutical Biotechnology mTOR: A Novel Therapeutic Target for Diseases of Multiple Systems
Current Drug Targets Clinical and Genetic Features of Warts, Hypogammaglobulinemia, Infections and Myelokathexis (WHIM) Syndrome
Current Molecular Medicine Bone Metastasis-Related MicroRNAs: New Targets for Treatment?
Current Cancer Drug Targets The Role of Epigenetics in Drug Resistance in Cancer
Epigenetic Diagnosis & Therapy (Discontinued) Advances in the Design and Development of PROTAC-mediated HDAC Degradation
Current Topics in Medicinal Chemistry Synthesis of resveratrol acrylamides derivatives and biological evaluation of their anti-proliferative effect on cancer cell lines
Letters in Drug Design & Discovery Therapeutic Targeting of Cancers with Loss of PTEN Function
Current Drug Targets Obesity and Inflammation: Colorectal Cancer Engines
Current Molecular Pharmacology Non-Covalent Proteasome Inhibitors
Current Pharmaceutical Design Antitumoral Potential of Snake Venom Phospholipases A2 and Synthetic Peptides
Current Pharmaceutical Biotechnology Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Meet Our Co-Editor
Drug Metabolism Letters Interleukin-18: Biology and Role in the Immunotherapy of Cancer
Current Medicinal Chemistry Recent Patents on Glioblastoma Signaling
Recent Patents on Biomarkers Cytokines as Anti-Angiogenic Agents in Haematological Malignancies
Current Cancer Drug Targets CXCL12-CXCR4 Axis in Angiogenesis, Metastasis and Stem Cell Mobilization
Current Pharmaceutical Design Tubulin-Targeting Agents in Hybrid Drugs
Current Medicinal Chemistry